PT910382E - Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores - Google Patents
Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumoresInfo
- Publication number
- PT910382E PT910382E PT97921396T PT97921396T PT910382E PT 910382 E PT910382 E PT 910382E PT 97921396 T PT97921396 T PT 97921396T PT 97921396 T PT97921396 T PT 97921396T PT 910382 E PT910382 E PT 910382E
- Authority
- PT
- Portugal
- Prior art keywords
- treatment
- treatment procedure
- squalamine
- procedure
- cytotoxic chemical
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 13
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 229940127084 other anti-cancer agent Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 12
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 abstract 3
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 231100000433 cytotoxic Toxicity 0.000 abstract 3
- 230000001472 cytotoxic effect Effects 0.000 abstract 3
- 229950001248 squalamine Drugs 0.000 abstract 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
- -1 BCNU) Chemical compound 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1638796P | 1996-04-26 | 1996-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT910382E true PT910382E (pt) | 2003-10-31 |
Family
ID=21776862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97921396T PT910382E (pt) | 1996-04-26 | 1997-04-25 | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6147060A (enExample) |
| EP (1) | EP0910382B1 (enExample) |
| JP (1) | JP2000510460A (enExample) |
| AT (1) | ATE242635T1 (enExample) |
| AU (1) | AU735884B2 (enExample) |
| CA (1) | CA2252584C (enExample) |
| DE (1) | DE69722793T2 (enExample) |
| DK (1) | DK0910382T3 (enExample) |
| ES (1) | ES2201296T3 (enExample) |
| PT (1) | PT910382E (enExample) |
| WO (1) | WO1997040835A1 (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| ATE375359T1 (de) * | 1998-08-12 | 2007-10-15 | Genaera Corp | Aminosterolderivate und ihre verwendungen |
| EP1119361A4 (en) * | 1998-09-10 | 2006-10-04 | Magainin Pharma | TREATMENT OF CARCINOMA WITH SQUALAMINE IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS |
| KR100704140B1 (ko) * | 1999-02-12 | 2007-04-09 | 더 스크립스 리서치 인스티튜트 | 혈관형성 억제제 및 항-종양 면역요법제를 포함하는, 종양 및 전이를 치료하기 위한 약제학적 조성물 및 이를 포함하는 키트 |
| US7820718B1 (en) | 1999-04-07 | 2010-10-26 | Roger Williams Hospital | Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer |
| ES2344831T3 (es) | 2000-06-23 | 2010-09-08 | Mitsubishi Tanabe Pharma Corporation | Potenciadores de un efecto antitumoral. |
| US20020073441A1 (en) | 2000-12-13 | 2002-06-13 | Ross Brian D. | Compositions and methods for detecting proteolytic activity |
| WO2003015707A2 (en) * | 2001-08-20 | 2003-02-27 | Transave, Inc. | Method for treating lung cancers |
| US6793912B2 (en) * | 2001-08-20 | 2004-09-21 | Transave Inc. | Treatment of cancers by inhalation of stable platinum-containing formulations |
| GB0126879D0 (en) * | 2001-11-08 | 2002-01-02 | Astrazeneca Ab | Combination therapy |
| EP1490027A4 (en) * | 2002-03-05 | 2010-11-10 | Transave Inc | METHODS OF TRAPPING BIOACTIVE AGENT IN A LIPOSOME OR LIPID COMPLEX |
| US9186322B2 (en) * | 2002-08-02 | 2015-11-17 | Insmed Incorporated | Platinum aggregates and process for producing the same |
| JP2006502233A (ja) * | 2002-08-02 | 2006-01-19 | トランセーブ，インク． | 白金凝集物およびその製造方法 |
| US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
| US7879351B2 (en) * | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
| KR101301653B1 (ko) * | 2002-10-29 | 2013-08-30 | 트랜세이브, 인코포레이티드 | 항감염제의 지속적인 방출 |
| US20080194019A1 (en) * | 2003-09-09 | 2008-08-14 | Beth Israel Deaconess Medical Center, Inc. | Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase |
| WO2005084710A2 (en) * | 2004-03-02 | 2005-09-15 | Massachusetts Institute Of Technology | Nanocell drug delivery system |
| US20070053845A1 (en) * | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
| JP2007529546A (ja) * | 2004-03-18 | 2007-10-25 | トランセイブ， インク． | 吸入によるシスプラチンの投与 |
| EP1755623A4 (en) * | 2004-05-21 | 2007-10-17 | Transave Inc | TREATMENT OF LUNG DISEASES AND BEFORE A PULMONARY DISEASE |
| WO2006039569A1 (en) * | 2004-09-30 | 2006-04-13 | The University Of Chicago | Combination therapy of hedgehog inhibitors, radiation and chemotherapeutic agents |
| EP1811963A4 (en) * | 2004-11-08 | 2010-01-06 | Transave Inc | METHOD FOR CREATING TREATMENT WITH INTRAPERITONEALLY APPLIED PLATINUM COMPOUND FORMULATIONS ON LIPID BASIS |
| US20070065359A1 (en) * | 2005-03-14 | 2007-03-22 | Shiladitya Sengupta | Nanocells for diagnosis and treatment of diseases and disorders |
| US7981876B2 (en) | 2005-04-25 | 2011-07-19 | Ohr Pharmaceuticals, Inc. | Polymorphic and amorphous salt forms of squalamine dilactate |
| WO2006119211A2 (en) * | 2005-05-02 | 2006-11-09 | Genaera Corporation | Methods and compositions for treating ocular disorders |
| US20060283742A1 (en) * | 2005-06-16 | 2006-12-21 | Canel Lightning Co. Ltd. | Multi-lamp display packaging for lamps with collapsible lampshades |
| US20070190182A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| US9107824B2 (en) | 2005-11-08 | 2015-08-18 | Insmed Incorporated | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally |
| US20070190181A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with lipid-based platinum compound forumulations administered intravenously |
| US20070190180A1 (en) * | 2005-11-08 | 2007-08-16 | Pilkiewicz Frank G | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously |
| WO2007064658A2 (en) * | 2005-11-30 | 2007-06-07 | Transave, Inc. | Safe and effective methods of administering therapeutic agents |
| ES2594368T3 (es) | 2005-12-08 | 2016-12-19 | Insmed Incorporated | Composiciones a base de lípidos de antiinfecciosos para tratar infecciones pulmonares |
| US20100047234A1 (en) * | 2007-03-14 | 2010-02-25 | Markovic Svetomir N | Treating skin cancer |
| US20100196455A1 (en) | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
| US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
| US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
| US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
| US9611313B2 (en) * | 2007-06-26 | 2017-04-04 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| RU2365370C1 (ru) * | 2008-04-29 | 2009-08-27 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | Способ лечения рака легкого |
| RU2367436C1 (ru) * | 2008-05-26 | 2009-09-20 | Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН | Способ лечения рака легкого |
| EP2310006A4 (en) | 2008-07-03 | 2012-04-25 | Mayo Foundation | CANCER TREATMENT |
| RU2388503C1 (ru) * | 2008-08-14 | 2010-05-10 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ лечения рака легкого |
| RU2402280C2 (ru) * | 2008-12-01 | 2010-10-27 | Федеральное государственное учреждение "Российский научно-исследовательский онкологический институт Росмедтехнологий" | Способ прогнозирования церебральных метастазов рака легкого |
| RU2406452C1 (ru) * | 2009-06-22 | 2010-12-20 | Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Росмедтехнологий" | Способ лечения рака легкого |
| RU2414894C1 (ru) * | 2009-06-29 | 2011-03-27 | Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН | Способ лечения рака легкого |
| US8729058B2 (en) * | 2009-10-27 | 2014-05-20 | Michael Zasloff | Methods and compositions for treating and preventing viral infections |
| US8623416B2 (en) * | 2009-11-25 | 2014-01-07 | Michael Zasloff | Formulations comprising aminosterols |
| RU2411018C1 (ru) * | 2009-12-22 | 2011-02-10 | Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" | Способ локальной химиотерапии метастазов в печень |
| RU2429842C1 (ru) * | 2010-06-15 | 2011-09-27 | Учреждение Российской академии медицинских наук Научно-исследовательский институт онкологии Сибирского отделения Российской академии медицинских наук (НИИ онкологии СО РАМН) | Способ профилактики послеоперационных осложнений при комбинированном лечении больных немелкоклеточным раком легкого iii стадии |
| US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| JP2015514708A (ja) * | 2012-03-30 | 2015-05-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 抗ｅｍｐ２療法による癌幹細胞の低減 |
| US10385395B2 (en) | 2012-04-11 | 2019-08-20 | The Regents Of The University Of California | Diagnostic tools for response to 6-thiopurine therapy |
| ES2905368T3 (es) | 2012-05-21 | 2022-04-08 | Insmed Inc | Sistemas para el tratamiento de infecciones pulmonares |
| CN105025904A (zh) | 2012-09-04 | 2015-11-04 | 埃莱森制药有限责任公司 | 用顺铂脂质复合物预防癌症的肺部复发 |
| AU2013327638B2 (en) | 2012-10-01 | 2018-06-14 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| WO2014085526A1 (en) | 2012-11-29 | 2014-06-05 | Insmed Incorporated | Stabilized vancomycin formulations |
| US10040817B2 (en) | 2013-10-03 | 2018-08-07 | Enterin Laboratories, Inc. | Methods and compositions for stimulation of the intestinal enteroendocrine system for treating diseases or conditions related to the same |
| BR112016026699B1 (pt) | 2014-05-15 | 2022-09-13 | Insmed Incorporated | Uso de uma composição farmaceutica de amicacina ou de um sal farmaceuticamente aceitável desta |
| MX380597B (es) | 2014-06-13 | 2025-03-12 | Mayo Found Medical Education & Res | Composición con complejos de nanopartículas/anticuerpos de paclitaxel unidos a albúmina para usarse al tratar linfoma. |
| US10213513B2 (en) | 2014-06-16 | 2019-02-26 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| WO2017120501A1 (en) | 2016-01-07 | 2017-07-13 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon |
| US11351254B2 (en) | 2016-02-12 | 2022-06-07 | Mayo Foundation For Medical Education And Research | Hematologic cancer treatments |
| WO2017165440A1 (en) | 2016-03-21 | 2017-09-28 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US11878061B2 (en) | 2016-03-21 | 2024-01-23 | Mayo Foundation For Medical Education And Research | Methods for improving the therapeutic index for a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| US11548946B2 (en) | 2016-09-01 | 2023-01-10 | Mayo Foundation For Medical Education And Research | Carrier-PD-L1 binding agent compositions for treating cancers |
| EP3506950A1 (en) | 2016-09-01 | 2019-07-10 | Mayo Foundation for Medical Education and Research | Methods and compositions for targeting t-cell cancers |
| EP3509643A1 (en) | 2016-09-06 | 2019-07-17 | Mayo Foundation for Medical Education and Research | Paclitaxel-albumin-binding agent compositions and methods for using and making the same |
| US11590098B2 (en) | 2016-09-06 | 2023-02-28 | Mayo Foundation For Medical Education And Research | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| US11427637B2 (en) | 2016-09-06 | 2022-08-30 | Mayo Foundation For Medical Education And Research | Methods of treating PD-L1 expressing cancer |
| US11083735B2 (en) | 2017-09-08 | 2021-08-10 | Enterin, Inc. | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions |
| US11674950B2 (en) * | 2017-10-31 | 2023-06-13 | Dana-Farber Cancer Institute, Inc. | Methods determining and treating cellular resistance to ADP-rtbosylating toxin |
| US11571386B2 (en) | 2018-03-30 | 2023-02-07 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
| CN116407640B (zh) * | 2023-03-03 | 2025-10-31 | 河南真实生物科技有限公司 | 包含阿兹夫定和化疗试剂的抗肿瘤药物组合物 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3016390A (en) * | 1960-06-30 | 1962-01-09 | Searle & Co | N-(substituted alkyl) amino-5alpha-androstan-17beta-ols |
| US3370070A (en) * | 1965-06-16 | 1968-02-20 | Searle & Co | [n-alkyl-17-(dialkylaminoalkyl)amino] androst-4-en-3-ones |
| GB1565351A (en) * | 1975-06-02 | 1980-04-16 | Theramex | Steroid aminoethers |
| US4220598A (en) * | 1977-11-14 | 1980-09-02 | Abbott Laboratories | Method and reagents for measuring the level of conjugated bile acids |
| US4550163A (en) * | 1979-02-05 | 1985-10-29 | Abbott Laboratories | Ligand analog-irreversible enzyme inhibitor conjugates |
| US4372888A (en) * | 1980-08-26 | 1983-02-08 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Nondenaturing zwitterionic detergents |
| JPS5842878B2 (ja) * | 1981-12-02 | 1983-09-22 | 名糖産業株式会社 | １２−オキソコラン酸トシルヒドラゾン化合物、その製法ならびに利用 |
| DE3366932D1 (en) * | 1982-07-29 | 1986-11-20 | Lehner Ag | New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same |
| US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| US5001116A (en) * | 1982-12-20 | 1991-03-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
| IT1221734B (it) * | 1983-02-24 | 1990-07-12 | Schiena Michele Giuseppe Di | Ursodesossicolico solfato acido sale sodico |
| US4545938A (en) * | 1983-11-02 | 1985-10-08 | Beth Israel Medical Center | Chemical synthesis |
| JPS6133121A (ja) * | 1984-07-25 | 1986-02-17 | Nissei Marine Kogyo Kk | 制癌剤 |
| EP0243449A1 (en) * | 1985-10-18 | 1987-11-04 | The Upjohn Company | Cyclic hydrocarbons with an aminoalkyl sidechain |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| JPS62175497A (ja) * | 1986-01-28 | 1987-08-01 | Wakunaga Pharmaceut Co Ltd | 胆汁酸誘導体およびその製造法 |
| US5075464A (en) * | 1987-04-22 | 1991-12-24 | Merrell Dow Pharmaceuticals Inc. | 17β-(cyclopropylamino)androstene derivatives |
| SE8702254D0 (sv) * | 1987-05-29 | 1987-05-29 | Kabivitrum Ab | Novel heparin derivatives |
| US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| IT1229569B (it) * | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| IT1229570B (it) * | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
| JPH07116215B2 (ja) * | 1989-04-19 | 1995-12-13 | エスエス製薬株式会社 | 新規なステロイド化合物 |
| PT93847A (pt) * | 1989-04-24 | 1990-11-20 | Harvard College | Processo para a preparacao de oligossacaridos de baixo peso molecular derivados de heparina ou de sulfato de heparano despolimerizados e de composicoes farmaceuticas que os contem |
| US4966897A (en) * | 1989-08-15 | 1990-10-30 | Merrell Dow Pharmaceuticals Inc. | 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors |
| US5004737A (en) * | 1989-09-22 | 1991-04-02 | Pacific Chemical Co., Ltd. | Quaternary ammonium-substituted sterol derivatives |
| EP0466315A3 (en) * | 1990-05-30 | 1992-07-01 | Larrian Gillespie | Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation |
| CA2081205C (en) * | 1990-06-11 | 2001-02-27 | John W. Wilks | Steroids which inhibit angiogenesis |
| EP0489423B1 (de) * | 1990-12-06 | 1996-11-06 | Hoechst Aktiengesellschaft | Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel |
| US5192756A (en) * | 1992-03-18 | 1993-03-09 | The Children's Hospital Of Pennsylvania | Aminosterol antibiotic |
| WO1993025197A1 (en) * | 1992-06-12 | 1993-12-23 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
| WO1994019366A1 (en) * | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
| DE69412596T2 (de) * | 1993-03-10 | 1999-03-04 | Magainin Pharmaceuticals Inc., Plymouth Meeting, Pa. | Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel |
| DE69429364T2 (de) * | 1994-03-10 | 2002-08-08 | Magainin Pharmaceuticals,Inc. | Verwendung von steroidderivaten als arzneimittel |
| US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
| ES2216049T3 (es) * | 1995-06-07 | 2004-10-16 | Genaera Corporation | Compuestos de aminosterol utiles como inhibidores del intercambiador de sodio/protones (nhe), metodos y composiciones farmaceuticas que emplean dichos inhibidores y procesos para evaluar la eficacia inhibidora de nhe de dichos compuestos. |
-
1997
- 1997-04-25 PT PT97921396T patent/PT910382E/pt unknown
- 1997-04-25 CA CA002252584A patent/CA2252584C/en not_active Expired - Lifetime
- 1997-04-25 DK DK97921396T patent/DK0910382T3/da active
- 1997-04-25 ES ES97921396T patent/ES2201296T3/es not_active Expired - Lifetime
- 1997-04-25 WO PCT/US1997/007011 patent/WO1997040835A1/en not_active Ceased
- 1997-04-25 JP JP09539076A patent/JP2000510460A/ja active Pending
- 1997-04-25 US US08/840,706 patent/US6147060A/en not_active Expired - Lifetime
- 1997-04-25 AT AT97921396T patent/ATE242635T1/de not_active IP Right Cessation
- 1997-04-25 AU AU27441/97A patent/AU735884B2/en not_active Ceased
- 1997-04-25 EP EP97921396A patent/EP0910382B1/en not_active Expired - Lifetime
- 1997-04-25 DE DE69722793T patent/DE69722793T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0910382A1 (en) | 1999-04-28 |
| AU2744197A (en) | 1997-11-19 |
| DE69722793D1 (de) | 2003-07-17 |
| ES2201296T3 (es) | 2004-03-16 |
| CA2252584C (en) | 2008-06-10 |
| CA2252584A1 (en) | 1997-11-06 |
| ATE242635T1 (de) | 2003-06-15 |
| EP0910382B1 (en) | 2003-06-11 |
| AU735884B2 (en) | 2001-07-19 |
| DE69722793T2 (de) | 2004-05-19 |
| US6147060A (en) | 2000-11-14 |
| DK0910382T3 (da) | 2003-10-06 |
| WO1997040835A1 (en) | 1997-11-06 |
| JP2000510460A (ja) | 2000-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT910382E (pt) | Esqualamina em combinacao com outros agentes anti-cancro para o tratamento de tumores | |
| DK1169059T3 (da) | Docetaxel i kombination med rhuMAb HER2 til behandling af cancere | |
| BR0109517A (pt) | métodos e composições sinérgicas para tratar o cáncer | |
| BR9709942A (pt) | Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo | |
| RU2007101378A (ru) | Терапия злокачественной опухоли, резистентной к препаратам на основе платины | |
| RU2007134571A (ru) | Комбинация и способы введения терапевтических средств и комбинированной терапии | |
| Dombernowsky et al. | Combination chemotherapy with 4′ Demethylepipodophyllotoxin 9-(4, 6-0-ethylidene-β-d-glucopyranoside), VP 16–213 (NSC 141540) in L1210 Leukemia | |
| TR200003879T2 (tr) | İn vivo ışın tedavisine duyarlılaştırıcı özelliklere sahip farnesil protein transferaz inhibitörleri@ | |
| BR0206046A (pt) | Usos de uma combinação e de sapogenina protopanaxadiol ou sapogenina protopanaxatriol, e, composição farmacêutica | |
| BRPI0510657A (pt) | tratamento com cisplatina e com um inibidor de egfr | |
| IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
| Reboul | Radiotherapy and chemotherapy in locally advanced non–small cell lung cancer: preclinical and early clinical data | |
| BRPI0517104A (pt) | tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico | |
| IL97055A0 (en) | Pharmaceutical compositions for sensitizing tumor cells comprising quinazolinedione derivatives | |
| SE8602743D0 (sv) | Injectable ready-to-use solutions containing an antitumor anthracycline glycoside | |
| Devizzi et al. | Vinorelbine: a new promising drug in Hodgkin's disease | |
| BRPI0517075A (pt) | uso de um inibidor de cinase de receptor de fator de crescimento epidérmico e radiação de ionização para tratamento de cáncer | |
| BR0309226A (pt) | Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável | |
| KR930700163A (ko) | 연조직 종양의 치료 및/또는 진단 방법 | |
| ES2134778T3 (es) | Bistriazenos como agentes quimioterapeuticos. | |
| Keizer et al. | Ifosfamide treatment as a 10-day continuous intravenous infusion | |
| BR9808263A (pt) | Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto. | |
| BR0214564A (pt) | Processos de tratamento de câncer utilizando um inibidor da fpt e agentes antineoplásicos | |
| Rodriguez-Galindo et al. | Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors | |
| BRPI0511780A (pt) | tratamento com oxoliplatina e um inibidor de egrf |